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Jutta Kirfel3, Reinhard Büttner1 and Ralf Weiskirchen2*Abstract
Background: Four and one half LIM domain protein 2 (FHL2) has been reported to be a key regulator in many
cellular processes being associated with fibrogenesis such as cell migration and contraction. Moreover, hepatic
FHL2 is involved in regulation pathways mediating proliferation and cell death machineries. We here investigated
the role of FHL2 in the setting of experimental and clinical liver fibrosis.
Methods: FHL2−/− and wild type (wt) mice were challenged with CCl4. Fibrotic response was assessed by
quantitative real time PCR (qRT-PCR) of fibrotic marker genes, measurement of hydroxyproline content and
histological methods. Murine FHL2−/− and hepatic stellate cells (HSC) were isolated and investigated via
immunofluorescence. Human fibrotic and normal liver samples were analysed immunohistochemically using
antibodies directed against FHL2.
Results: FHL2−/− mice displayed aggravated liver fibrosis compared to wt mice. However, immunofluorescence
revealed no significant morphological changes in cultured FHL2−/− and wt myofibroblasts (MFB). In human liver
samples, FHL2 was strongly expressed both in the nucleus and cytoplasm in MFB of fibrotic livers. In contrast, FHL2
expression was absent in normal liver tissue.
Conclusions: Deficiency of FHL2 results in aggravation of murine liver fibrosis. In human liver samples, FHL2 is
expressed in activated HSCs and portal fibroblasts in human fibrotic livers, pointing to a central role of FHL2 for
human hepatic fibrogenesis as well.Background
Liver fibrosis is characterized by a significant increase of
collagenous matrix. Complete organ fibrosis represents
the final course of several chronic progressive liver dis-
eases and end-stage liver disease is associated with a
high morbidity and mortality. Myofibroblastic activated
HSC represent the key fibrogenic cells in the liver. Be-
sides the production of extracellular matrix, these cells
show increased proliferation, migration and contraction.
To date, hepatic fibrosis is seen as a complex wound
healing process, not being fully understood [1].
FHL2 belongs to the superfamily of LIM domain
proteins, which harbour a common zinc finger do-
main allowing flexible protein-protein interaction [2,3].* Correspondence: rweiskirchen@ukaachen.de
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reproduction in any medium, provided the orDepending on the number of LIM-domains, five subfam-
ilies are to be distinguished [4]. FHL2 belongs to the fam-
ily of four an a half LIM domain proteins. This family is
known to interact with integrins at the plasma membrane
and function as transcriptional coactivator after nuclear
translocation [5]. FHL2 has been shown to play an active
part in fibrogenesis both in wound healing and tumor
stroma. In line, it was found that mice that are deficient
for FHL2 are characterized by a delayed healing of skin
wounds and an overall reduced transcriptional activation
of smooth muscle actin and reduced contractility of MFB
[6]. In addition, it was reported that FHL2-deficiency leads
to disturbed intestinal wound healing [7]. Most recently,
Gullotti et al. observed that FHL2 activation and nuclear
transactivation occurs much more intensively in sporadic
colon cancers than in microsatellite-instable, hereditary
colon cancer and correlates with intensive tissue remodel-
ling and advanced metastasis [8]. Furthermore, transgenic
mice constitutively overexpressing FHL2 in the liver wered. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was associated with concomitant apoptosis resulting in
normal liver mass suggesting that FHL2 is a crucial gate-
keeper that controls fundamental hepatic processes and
liver diseases [9].
As FHL2 has been shown be involved in different
forms of fibrogenesis and transdifferentiation of cells
into a MFB-like, contractile cell phenotype, we aimed at
investigating whether FHL2 is involved in hepatic fibro-
genesis as well.
Methods
Animals
Male C57BL/6 mice (Harlan Laboratories, Eystrup,
Germany) aged 10–12 weeks were kept under controlled
environmental conditions with a 12-h light–dark cycle.
Mice were fed on a standard laboratory diet with food
and water ad libitum. FHL2−/− knockout mice were
bread into C57Bl/6 background for more than tenBilirubin
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Figure 1 Serum analysis in wild-type and FHL2-deficient mice after C
challenge. Biochemical markers were investigated in serum samples of wt
for (A) aspartate transaminase (AST), (B) alanine aminotransferase (ALT), (C)generations. All animal experiments were approved by
the Landesamt für Natur, Umwelt und Verbrau-
cherschutz NRW (LANUV), Recklinghausen, Germany
under reference number 8.87-51.04.20.09.
Induction of liver fibrosis
Six to eight weeks old wt mice (n = 9) or FHL2-deficient
mice (n = 12) weighing approximately 18–20 g received
intraperitoneal injections twice weekly of 0.7 ml/kg body
weight of CCl4 in equal volume of mineral oil for up to
6 weeks (i.e. a total of 12 i.p. injections), whereas mineral
oil alone was used as controls in wt animals (n = 4) or
FHL2-deficient mice (n = 4).
Tissue collection
After 6 weeks of treatment, the animals were sacrificed
by cervical dislocation. The livers were removed and
samples snap-frozen in liquid nitrogen and stored
at −80°C or fixed in formaldehyde (4%). Blood wasProtein
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Cl4 challenge. Serum analysis in wt and FHL2-deficient mice after CCl4
or FHL2 deficient mice that received CCl4 or mineral oil and are shown
bilirubin, and (D) total protein.
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serum was stored at −80°C until further analysis.
Measurement of serum parameters
Blood biochemical parameters (bilirubin, ALT, AST and
total protein) were measured using the Modular Pre-
Analytics (MPA) system (Roche Diagnostics, Mannheim,
Germany).
Histology and immunohistochemistry
After 24 hours fixation in 4% buffered formalin, the liver
specimens were embedded into paraffin. Histological
quantitative examination of liver fibrosis was performed
on sections after standard Sirius Red staining. For the
morphometric analysis of Sirius Red-stained specimens, at
least 10 mm2 of liver tissue was analysed by means of
computational analysis (Histoquant, 3DHistech, Budapest,
Hungary). Large bile ducts and vessels were excluded. The
principle of computational analysis has been described
elsewhere [10,11]. For the analysis of activated HSC in
wt and FHL2−/− livers, paraffin liver sections werewt
FHL2-/-
sham CC
A B
C D
Figure 2 Hepatic fibrosis in wt and FHL2-deficient mice after CCl4 cha
(A-D) Sirius Red and representative images were made using a standard lig
quantified by (E) densitometry or by measuring (F) direct hepatic hydroxyp
(*), and highly significant differences (**-***) are marked.co-stained with antibodies for collagen III (anti-col-
lagen III, Biozol/SouthernBiotech, Eching, Germany)
and α-SMA (anti-α-SMA, clone E184, Biomol/Epitomocs,
Hamburg, Germany).
Hepatic hydroxyproline content
Hepatic hydroxyproline content was determined in
analogue segments (50 mg) of snap-frozen livers using
standard methods. The results are calculated as mg/g of
wet liver tissue.
Quantitative RT-PCR
RNA isolation, reverse transcription with 0.5 μg total
RNA, and detection by RT-PCR were performed as
previously described [12]. Most of the primers and
probes for RT-PCR were obtained as a ready-to-use mix
(α-SMA, Fibronectin, TGF-β, Procollagen Iα, from Ap-
plied Biosystems, Foster City, USA). Murine GFAP was
amplified using primers mGFAPf (50-CCT TCT GAC
ACG GAT TTG GT-30) and mGFAPr (50-ACA GAC
TTT CTC CAA CCT CCA G-30) and murine fibulin-2l4
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Figure 3 Expression analysis of genes associated with fibrogenesis in mice subjected to CCl4 challenge. RNA was isolated from livers of
wt or FHL2 deficient mice that received CCl4 or mineral oil and analyzed for expression of collagen type αI, collagen type III, α-SMA, TGF-α,
laminin and fibronectin by qRT-PCR analysis. Non significant differences (ns), significant differences (*), and highly significant differences (**-***)
are indicated.
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http://www.biomedcentral.com/1471-230X/13/8was amplified using primers mFbln2f (50-CCA TCA
AAC ACT CGT CTT GGT-30) and mFbln2r (50-TGT
TGT TGG GGA CAC AGC TA-30), respectively.
GAPDH served as endogenous control (primers and
probes ready-to-use mix by Applied Biosystems). RT-PCR (ABI 7300 sequence detector) and PCR reaction
(2x TaqMan-PCR-mastermix, Applied Biosystems) were
performed as previously described [12]. For each of the
genes, a validation experiment was performed. Efficien-
cies of RT-PCR for the target gene and the endogenous
7 d 
wt 
2 d 7 d 2 d 
HSC MFB 
FHL2-/- 
Figure 4 Transdifferentiation of isolated HSC to MFB. HSC from wt and FHL2 deficient mice were isolated by FACS-based protocols and
plated on plastic surfaces for 2 or 7 days. For generation of fully transdifferentiated MFB, the cells were passaged once and cultured for an
additional 2 or 7 day period. At indicated time points, the cells were fixed in 4% paraformaldehyde and stained with a rhodamine-phalloidin-
conjugate. Note the typical appearance of F-actin fibres in both cell phenotypes that are highly characteristic for activated HSC and
transdifferentiated MFB.
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http://www.biomedcentral.com/1471-230X/13/8control were approximately equal. -ΔCT expresses the
difference between number of cycles (CT) of the target
genes and the endogenous control. Results were
expressed as 2-ΔΔCt, and express the x-fold increase of
gene expression compared to control group.
Cell culture
Primary HSC from wt and FHL2 deficient mice were iso-
lated by pronase-collagenase perfusion following by FACS-
based purification protocols [13]. 10 × 104 cells each were
seeded onto glass coverslips and cultivated in Dulbecco’s
modified Eagle medium (Lonza BioWhittaker, Verviers,
Belgium) supplemented with 10% FCS (PAA Laboratories,
Pasching, Austria), 4 mM L-Glutamine (Lonza), 100 U/ml
penicillin and streptomycin (Lonza). For generation of fully
transdifferentiated MFB, the cells were passaged once and
cultured for an additional 2 or 7 day period. At indicatedA
Figure 5 Collagen III/α-SMA expression in wt and FHL2-deficient mice
deficient mice showed a stronger collagen III (green) expression after CCl4 c
(brown) expression.time points, the cells were fixed in 4% paraformaldehyde
for 10 min and stained with a rhodamin phalloidin.
FHL2 immunohistochemistry in human liver fibrosis
We investigated the expression of FHL2 immunohisto-
chemically in three samples of human liver fibrosis.
Normal liver served as control. The staining procedure
was carried out as described earlier [8]. In brief, immu-
nohistochemistry was performed on 4-μm-thick paraffin-
embedded sections by use of the peroxidase-conjugated
avidin–biotin method. Primary antibodies included
FHL2 (kind gift of R. Schüle, University Hospital Freiburg,
Freiburg, Germany) and α-SMA (clone 1A4, DAKO,
Hamburg, Germany, 1:4000).
Statistical analysis
Data are presented as mean±standard error of the mean
(SEM). Student’s t-test was used for comparison whereB
after CCl4 challenge. Compared to (A) wt littermates, (B) FHL2-
hallenge (400x). However, there was no obvious difference in α-SMA
AB
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Figure 6 Expression of Fibulin-2 and GFAP in wt and FHL2-
deficient mice subjected to CCl4 challenge. Expression of (A)
Fibulin-2 (marker of portal fibroblasts) and (B) GFAP (marker of HSC)
was analysed in wt and FHL2 deficient mice after CCl4 challenge.
Animal numbers analysed in this experiment were: n = 4 (wt, oil),
n = 11 (wt, CCl4), n = 4 (FHL2
−/−, oil), and n = 12 (FHL2−/−, CCl4).
Please note that the differences in fibulin-2 expression between wt
and FHL2−/− animals after CCl4 challenge are highly significant (***).
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Results
Hepatocellular injury after CCl4-treatment
The aminotransferases ALT and AST were significantly
increased after CCl4 treatment in both wt and FHL2
−/−
mice compared to their sham treated littermates
(Figure 1, upper panels). Significant changes were noted
between CCl4-challenged wt and knockout mice con-
cerning ALT, but not AST. Bilirubin and protein levels
remained almost unchanged in all groups (Figure 1,
lower panels).
Hepatic fibrosis in mice
After CCl4-treatment, hepatic fibrosis was observed in
wt and FHL2−/− mice. Interestingly FHL2−/− micedeveloped significantly aggravated liver fibrosis com-
pared to respective wt control mice as demonstrated in
Sirius Red stain (Figure 2A-2D). This finding was also
confirmed by both morphometric analysis of Sirius Red
stained histological slides (Figure 2E) and measurement
of hepatic hydroxyproline content as the main amino
acid of collagen (Figure 2F). After CCl4 challenge, the
lack of FHL2 further resulted in an increased expression
of collagen type III, TGF-β1, and laminin (Figure 3),
while the mRNA quantities of Collagen type I, α-SMA
and fibronectin were not statistically different between
control and FHL2 deficient mice.
Hepatic stellate cell activation in mice
To test if HSC isolated from wt and FHL2 deficient
show a different tendency to become activated in cul-
ture, we isolated primary HSC from respective animals
using established procedures. The typical appearance of
F-actin fibres in both cell phenotypes was noted that is
highly characteristic for activated HSC and transdifferen-
tiated MFB. However, no significant differences between
the two genotypes were noted suggesting that the gene
deficiency does not interfere with cellular activation or
transdifferentiation per se (Figure 4).
To further analyze the expression pattern of activated
HSC in wt and FHL2 deficient livers, paraffin liver sec-
tions were co-stained with antibodies specific for colla-
gen III and α-SMA. In this analysis, FHL2-deficient mice
revealed a stronger collagen III expression after CCl4
challenge compared to wt animals (Figure 5). However,
there were again no significant differences in α-SMA
expression (not shown). However, the expression of
Fibulin-2 representing a marker of portal fibroblasts
[14,15] was extensively increased at the mRNA level in
FHL2 deficient mice subjected to CCl4 treatment
(Figure 6A) and expression of GFAP representing a mar-
ker of HSC was more or less the same (Figure 6B).
FHL2 expression in human liver fibrosis
We investigated FHL2 expression in normal and fibrotic
liver samples (Figure 7). In normal healthy liver, FHL2
staining was nearly absent. Stromal cells occasionally
revealed weak nuclear FHL2 expression. In fibrotic liver,
however, MFB and portal fibroblasts showed a strong
nuclear and cytoplasmatic expression of FHL2 in fibrotic
septa. A similar staining pattern was observed in cul-
tured murine HSC undergoing transdifferentiation
(not shown).
Discussion
This study shows for the first time that FHL2 is crucial
in experimental liver fibrosis. When we challenged
FHL2-deficient mice with CCl4, we observed that FHL2-
deficient mice displayed aggravated liver fibrosis
C D
E F
A B
Figure 7 FHL2 expression in normal and fibrotic human liver samples. Normal (A, 200x, HE) and fibrotic liver samples (B, 200X, HE) were
investigated using antibodies against α-SMA and FHL2. In normal liver, α-SMA expression was low (C, 200x), whereas in fibrotic liver samples a
strong reactivity was found especially in activated MFB (D, 200x). FHL2 expression was negative in normal liver (E, 200x). In contrast, MFB revealed
strong nuclear (arrows) as well as cytoplasmatic staining in fibrotic liver samples (F, 200x).
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lysis of Sirius Red-stained histological slides and direct
measurement of hepatic hydroxyproline content in liver
protein extracts that is indicative for deposited collagen.
Therefore, our findings suggest a protective mechanistic
role of FHL2 during hepatic fibrogenesis.
Kirfel et al. reported impaired intestinal wound healing
in FHL2-deficient mice. They identified disturbed colla-
gen type III production being responsible for reduced
mechanical stability of experimental intestinal anasto-
moses. They concluded that FHL2 is a critical factor
regulating collagen expression in the early phase of
wound healing.
In normal liver, collagen type I and III are found in
portal tracts and around hepatic veins. During liver fi-
brosis, excess collagen type I and III are deposited not
only in portal tracts but also in the lobule leading to
major architectural changes. In the present study aggra-
vated liver fibrosis was especially associated with upre-
gulated collagen III expression in mice lacking FHL2
and subjected to CCl4-treatment. Interestingly, thesefindings are different than those observed in intestinal
wound healing possibly reflecting the different biological
behaviour of different cell entities involved in fibrogen-
esis in different organs. Concerning different cell types,
FHL2 has been shown to interact as a cofactor regulat-
ing a variety of target genes. In ovarian granulosa cells,
FHL2 was found to be a coactivator of NR5A nuclear
receptors [16]. In prostate cancer, FHL2 acts as a coacti-
vator, shifts to the nucleus and subsequently activates
FHL2- and androgen receptor-dependent genes [17]. In
our human liver fibrosis samples studied, MFB showed a
strong nuclear and cytoplasmatic expression of FHL2.
We therefore hypothesize, that FHL2 acts probably as a
coactivator regulating important target genes in the
setting of liver fibrosis as well.
Park et al. showed that FHL2 is involved in bundling
of focal adhesion structures and in proper allocation of
matrix proteins [18]. In our experiments, fibronectin
was upregulated in both wt and FHL2−/− mice (Figure 3),
whereas laminin was only strongly upregulated in FHL2
deficient mice and not in wt mice. However, we have
Huss et al. BMC Gastroenterology 2013, 13:8 Page 8 of 9
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directly involved in FHL2 functionality during hepatic
fibrogenesis, other LIM domain proteins such as the
LIM only protein Hic-5 are also known to influence lam-
inin expression [19]. Although we have actually no
further data that highlight the activity of FHL2 in
laminin expression, it will be mandatory to clarify if this
regulation is a general attribute of individual classes of
LIM domain proteins.
The recent finding demonstrating that FHL2 controls
liver homeostasis by co-ordinately regulating cell prolif-
eration and cell death in hepatocytes [8] and our find-
ings demonstrating that FHL2 might be an essential
factor in controlling hepatic fibrogenesis via regulating
HSC activation and transdifferentiation. It further sug-
gests that this LIM domain in liver is multi-functional
impacting crucial processes involved in control of liver
homeostasis. However, we could not detect a difference
in HSC transdifferentiation in vitro (Figure 4), either
suggesting that (i) the gene deficiency induces only dif-
ferences in vivo or that (ii) the antifibrotic functionality
of FHL2 is more pronounced in portal fibroblasts. In
our view, the second possibility is more likely since the
expression of fibulin-2 representing a marker of fibro-
genic portal fibroblasts is highly significant upregulated
in FHL2 deficient mice when subjected to CCl4 chal-
lenge (Figure 6A) , while the expression of GFAP correl-
ating with HSC numbers is the same in FHL2 deficient
and control animals under these conditions (Figure 6B).
Conclusions
We show that deficiency of FHL2 results in aggravation
of murine liver fibrosis. In human liver samples, FHL2 is
expressed in activated HSCs and portal fibroblasts in
human fibrotic livers, pointing to a central role of FHL2
for human hepatic fibrogenesis as well. Altogether, these
findings indicate that this LIM domain protein is most
relevant when liver homeostasis is affected.
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